Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page instead of the study record content. The new page shows a minimal header with a Home link, indicating restricted access to the record rather than substantive study information.
    Difference
    20%
    Check dated 2026-09-23T00:22:47.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision updated from v3.6.6 to v3.7.0, indicating a newer version of the page template or CMS. No study-related content is altered.
    Difference
    0.0%
    Check dated 2026-09-15T23:50:00.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.6.6, indicating a small update to the study record without altering displayed content.
    Difference
    0.0%
    Check dated 2026-09-01T20:00:27.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The study record now shows a funding attribution: '2023 ( U.S. NIH Grant/Contract )', indicating NIH support for the trial. This addition updates the record to disclose the study's funding source.
    Difference
    0.0%
    Check dated 2026-08-25T21:41:38.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5 on the page, indicating a new published revision. This reflects a maintenance/version update rather than a substantive change to the page's content.
    Difference
    0.0%
    Check dated 2026-08-11T16:37:35.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Plain Language Summary has been removed from the page, removing a lay-friendly overview of the trial. Readers will need to consult the more technical sections for study details.
    Difference
    0.0%
    Check dated 2026-08-04T14:55:25.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.